BRPI0409865A - injeção intravenosa de ativadores de plasminogênio não neurotóxicos para o tratamento do ataque de apoplexia - Google Patents

injeção intravenosa de ativadores de plasminogênio não neurotóxicos para o tratamento do ataque de apoplexia

Info

Publication number
BRPI0409865A
BRPI0409865A BRPI0409865-0A BRPI0409865A BRPI0409865A BR PI0409865 A BRPI0409865 A BR PI0409865A BR PI0409865 A BRPI0409865 A BR PI0409865A BR PI0409865 A BRPI0409865 A BR PI0409865A
Authority
BR
Brazil
Prior art keywords
intravenous injection
plasminogen activators
neurotoxic plasminogen
neurotoxic
stroke attack
Prior art date
Application number
BRPI0409865-0A
Other languages
English (en)
Inventor
Mariola S Hngen
Wolfgang S Hngen
Wolf-Dieter Schleuning
Robert Medcalf
Original Assignee
Paion Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2003/004729 external-priority patent/WO2004096267A1/de
Application filed by Paion Deutschland Gmbh filed Critical Paion Deutschland Gmbh
Publication of BRPI0409865A publication Critical patent/BRPI0409865A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"INJEçãO INTRAVENOSA DE ATIVADORES DE PLASMINOGêNIO NãO NEUROTóXICOS PARA O TRATAMENTO DO ATAQUE DE APOPLEXIA". A invenção refere-se à aplicação de fatores ativadores de plasminogênio não neurotóxicos, por exemplo, de Desmodus rotundus (DSPA) ou de fatores ativadores de plasminogênio geneticamente modificados, especialmente de origem humana para a preparação de um terápico injetável para o tratamento terapêutico do ataque de apoplexia no homem.
BRPI0409865-0A 2003-05-02 2004-04-30 injeção intravenosa de ativadores de plasminogênio não neurotóxicos para o tratamento do ataque de apoplexia BRPI0409865A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2003/004608 2003-05-02
PCT/EP2003/004729 WO2004096267A1 (de) 2003-05-02 2003-05-06 Intravenöse injektion nicht-neurotoxischer plasminogen-aktivatoren zur behandlung von schlaganfall
PCT/EP2004/004626 WO2004096268A2 (de) 2003-05-02 2004-04-30 Intravenöse injektion nicht-neurotoxischer plasminogen-aktivatoren zur behandlung von schlaganfall

Publications (1)

Publication Number Publication Date
BRPI0409865A true BRPI0409865A (pt) 2006-05-16

Family

ID=35610451

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409865-0A BRPI0409865A (pt) 2003-05-02 2004-04-30 injeção intravenosa de ativadores de plasminogênio não neurotóxicos para o tratamento do ataque de apoplexia

Country Status (10)

Country Link
EP (1) EP1622639B1 (pt)
JP (1) JP2006525270A (pt)
KR (1) KR101212631B1 (pt)
BR (1) BRPI0409865A (pt)
CA (1) CA2524573A1 (pt)
HR (1) HRP20050903B1 (pt)
NO (1) NO337485B1 (pt)
NZ (1) NZ543367A (pt)
PL (1) PL1622639T3 (pt)
WO (1) WO2004096268A2 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10153601A1 (de) 2001-11-02 2003-05-22 Paion Gmbh DSPA zur Behandlung von Schlaganfall
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
DE10342518A1 (de) * 2003-09-12 2005-05-12 Paion Gmbh Plasminogen-Aktivatoren mit verringerter Lysin-Bindungskapazität
NZ561664A (en) 2005-02-24 2011-02-25 Diffusion Pharmaceuticals Llc Trans carotenoids, their synthesis, formulation and uses
EP1897554A1 (en) * 2006-08-25 2008-03-12 PAION Deutschland GmbH Method for the manufacture of a medicament for treating hemorrhagic stroke
WO2008022801A1 (en) * 2006-08-25 2008-02-28 Paion Deutschland Gmbh Method for the manufacture of a medicament for treating hemorrhagic stroke
CN101687757A (zh) 2007-04-13 2010-03-31 扩散药品有限公司 双极性反式类胡萝卜素作为预治疗及其在周围血管疾病的治疗中的应用
HRP20210112T1 (hr) 2009-06-10 2021-04-16 Nono Inc. Režimi liječenja namijenjeni liječenju neurološke bolesti
EP2445339B1 (en) * 2009-06-22 2019-08-07 Diffusion Pharmaceuticals LLC Diffusion enhancing compound and its use with a thrombolytic
JP5823672B2 (ja) * 2009-07-27 2015-11-25 国立大学法人 新潟大学 受容体シグナル伝達阻害剤を含む脳梗塞治療用医薬品組成物
US8652476B2 (en) 2009-07-27 2014-02-18 Niigata University Pharmaceutical composition for treating ischemic events
JP5823671B2 (ja) * 2009-07-27 2015-11-25 国立大学法人 新潟大学 免疫製剤を含む脳梗塞治療用医薬品組成物
JP2013527231A (ja) 2010-06-02 2013-06-27 ディフュージョン・ファーマシューティカルズ・エルエルシー 双極性トランスカロテノイドの経口製剤
CA2839630A1 (en) 2011-06-24 2012-12-27 Nono Inc. Combination therapy for ischemia
US9241970B2 (en) 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
CN109152839A (zh) 2016-03-24 2019-01-04 扩散药品有限公司 双极性反式类胡萝卜素连同化疗和放射治疗在治疗癌症中的用途
US10617756B2 (en) 2017-01-05 2020-04-14 Shimojani, LLC Drug regimen for treatment of cerebral ischemia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI100403B (fi) * 1988-07-20 1997-11-28 Schering Ag Menetelmä glykosyloitujen tai glykosyloimattomien vampyyrilepakon sylj en plasminogeeniaktivaattoreiden valmistamiseksi
NL8902454A (nl) * 1989-10-03 1991-05-01 Stichting Centraal Lab Mutanten van de humane plasminogeen activator inhibitor 1 (pai-1), hun bereiding en toepassing, en recombinante polynucleotiden die voor deze mutanten coderende genetische informatie omvatten.
DE10153601A1 (de) * 2001-11-02 2003-05-22 Paion Gmbh DSPA zur Behandlung von Schlaganfall

Also Published As

Publication number Publication date
NZ543367A (en) 2010-06-25
KR20060020616A (ko) 2006-03-06
KR101212631B1 (ko) 2012-12-14
PL1622639T3 (pl) 2013-06-28
WO2004096268A2 (de) 2004-11-11
EP1622639B1 (de) 2013-01-16
NO20055692D0 (no) 2005-12-01
WO2004096268A3 (de) 2005-04-21
NO337485B1 (no) 2016-04-25
CA2524573A1 (en) 2004-11-11
NO20055692L (no) 2006-01-30
HRP20050903A2 (en) 2006-08-31
JP2006525270A (ja) 2006-11-09
HRP20050903B1 (hr) 2013-11-22
EP1622639A2 (de) 2006-02-08

Similar Documents

Publication Publication Date Title
BRPI0409865A (pt) injeção intravenosa de ativadores de plasminogênio não neurotóxicos para o tratamento do ataque de apoplexia
WO2003032994A3 (de) 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren
EA200801570A1 (ru) Стабильные белковые препараты
EP1425031B8 (en) Hdl for the treatment of stroke and other ischemic conditions
BR9906813A (pt) Método para administração de insulina aspb28- humana
IL171607A (en) Use of botulinum toxin for the treatment of sinusitis-induced headaches
BRPI0410029B8 (pt) composto dihidroquinazolina substituído, processo para sua preparação, medicamento compreendendo o referido composto e uso do referido composto
CY1109648T1 (el) Μη νευροτοξικοι παραγοντες ενεργοποιησης πλασμινογονου για την αγωγη εγκεφαλικου επεισοδιου
MY145590A (en) Phenylacetamides and their use as glucokinase modulators
DK1151009T3 (da) Antimikrobielt/endotoksin-neutraliserende polypeptid
BR0209129A (pt) Compostos, composições farmacêuticas, métodos para tratamento de dores, métodos para modulação de uma resposta farmacológica e usos de compostos
CY1107640T1 (el) Μεθοδος για πιστοποιηση παραγοντων για τη θεραπεια διαβητη
BRPI0515896A (pt) composto ou um sal ou éster farmaceuticamente aceitável do mesmo, método para o tratamento ou profilaxia de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus, e, composição farmacêutica para o tratamento de um hospedeiro infectado com uma infecção por flavivìrus, pestivìrus ou hepacivìrus
MXPA04005156A (es) Antagonistas del receptor de adenosina a2a.
BR0015992A (pt) Compostos, utilização dos mesmos, e, associações terapêuticas
BR0316523A (pt) Composto, composição farmacêutica e método para tratar ou prevenir câncer em um paciente
BR0208727A (pt) Eritropoietina melhorando a toxicidade in vivo induzida por quimioterapia
BR0213293A (pt) Uso de tfpi ou de um análogo de tfpi no tratamento de septicemia
BR0107628A (pt) l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico
BR0201524A (pt) Tratamento de combinação para ansiedade e depressão
WO2004103267A3 (en) Methods to administer epothilone d
EP4487909A3 (en) Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
CY1114254T1 (el) Ενδοφλεβια ενεση μη νευροτοξικων ενεργοποιητων του πλασμινογονου για την αντιμετωπιση του εγκεφαλικου επεισοδιου
ATE554793T1 (de) Konjugat

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: H. LUNDBECK A/S. (DK)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B25E Requested change of name of applicant rejected

Owner name: H. LUNDBECK A/S. (DK)

B08F Application fees: application dismissed [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]